The Global Conjunctivitis Market is projected to grow with a CAGR between 2.1% and 2.5% during 2016-2022 and reach USD X.XX billion by 2022. Conjunctivitis or pink eye is an inflammation or redness of the lining of the white part of the eye and the underside of the eyelid that can be caused by infection, allergic reaction, or physical agents like infrared or ultraviolet light. Conjunctivitis is an extremely common eye problem because the conjunctiva is continually exposed to microorganisms and environmental agents that can cause infections or allergic reactions. It can also affect one or both eyes and, if caused by infection, can be very easily transmitted to others during close physical contact, particularly among children in a daycare center. Thus, people diagnosed with conjunctivitis are recommended not to travel public places for that period of time.

Increasing awareness among patient population about pink eye disease, entry of new drugs and unmet need for viral conjunctivitis are considered to be the key factors driving the growth of this market. Unfavorable government regulations, expiring drug patents of major blockbusters and the growing demand for antibacterial drugs has impacted the demand for branded drugs are the key restraining factors for the growth of this market. Since, there are no approved drugs for the treatment of viral conjunctivitis, many companies are developing drugs which are expected to aid in the treatment of viral conjunctivitis and their effect will turn into a prominent opportunity to promote growth of this market over the forecast period. Moreover, loss of patent exclusivities and increasing demand for generic antibacterial drugs over branded drugs are the major challenges faced by this market.

Segments Covered:

The report segments the conjunctivitis market by disease type and by region. Market segmentation based on disease type includes Bacterial conjunctivitis, viral conjunctivitis and Allergic conjunctivitis. Furthermore, Allergic conjunctivitis segment is anticipated to grow at the highest CAGR over the forecast period accounted for more than 45% of the total market share by 2022. The key factor driving the growth of allergic conjunctivitis segment, are considered to be the different allergies present in the environment such as cold, acute respiratory infection, or other diseases such as measles, herpes simplex , or herpes zoster.

Geographic Coverage and Analysis:

The report provides regional analysis covering geographies such as North America, Europe, Asia Pacific, Latin America and Rest of the World (RoW). North America along with Latin America accounted for the largest market share together occupying more than 50% share of global market and is expected to continue its dominance over the forecast period. Increasing awareness among the patient and availability of multiple treatment options are expected to drive the growth in this region. Moreover, Asia Pacific is anticipated to grow at the highest CAGR over the forecast period and provides the opportunity for market growth due to presence of major players and increasing R&D activities.

Companies Profiled:

The companies covered in the report include

Akorn
Alcon
Allergan, Inc.
Bausch & Lomb
Celsus Therapeutics
Eleven Biotherapeutics
Griffin Discoveries
InSiteVision
Merck
Nicox
NovaBay
Ocular Therapeutix
Santen Pharmaceutical
Starpharma
Sun Pharma
Pfizer, Inc.